Quick Answer
Arcutis Biotherapeutics, Inc. reported Total Assets of $432.97 million for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +24.1% in Total Assets from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $254.39 million | Q2 2020: $231.97 million | Q3 2020: $198.01 million | Q1 2021: $471.42 million | Q2 2021: $432.89 million | Q3 2021: $387.01 million | Q1 2022: $364.11 million | Q2 2022: $300.46 million | Q3 2022: $508.91 million | Q1 2023: $379.46 million | Q2 2023: $320.69 million | Q3 2023: $292.96 million | Q1 2024: $478.54 million | Q2 2024: $444.76 million | Q3 2024: $437.35 million | Q1 2025: $344.11 million | Q2 2025: $352.43 million | Q3 2025: $370.98 million.
- Over the full 7 years of available data (2019 to 2025), Arcutis Biotherapeutics, Inc.'s Total Assets has grown by 304.6%.
- Historical annual values: Fiscal year 2025: $432.97 million | Fiscal year 2024: $348.89 million | Fiscal year 2023: $341.37 million | Fiscal year 2022: $449.27 million | Fiscal year 2021: $408.15 million | Fiscal year 2020: $298.27 million | Fiscal year 2019: $107.01 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: